知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

135 条记录 (耗时 0.033 秒)

    Method of administering high-dose, oral magnesium for treatment of chronic pain syndrome of erythromelalgia
    1.
    发明授权
    Method of administering high-dose, oral magnesium for treatment of chronic pain syndrome of erythromelalgia 失效
    用于治疗慢性红斑性疼痛综合征的大剂量口服镁的方法

    公开(公告)号：US06835398B2

    公开(公告)日：2004-12-28

    申请号：US10292639

    申请日：2002-11-12

    申请人： Jay S. Cohen

    发明人： Jay S. Cohen

    IPC分类号： A61K3119

    CPC分类号： A61K33/06 ,  A61K33/08 ,  A61K33/14 ,  Y10S514/867 ,  Y10S514/905 ,  Y10S514/964

    摘要： A method of treating patients, particularly for pain and/or symptoms of erythromelalgia, and other neurovascular or neuropathic disorders, etc. involves administering high doses of magnesium. The magnesium is introduced through several daily administrations, totaling approximately 2-12 times the RDA for magnesium. These higher levels are achieved through increasing daily dosage amounts gradually in response to patient tolerance and until beneficial results are seen. Total magnesium intake is divided over several doses per day and taken with copious amounts of water.

    摘要翻译： 一种治疗患者的方法，特别是用于治疗红斑性疼痛和/或症状的其它神经血管或神经性疾病等，包括施用高剂量的镁。 通过几次日常施用引入镁，总共约为镁的RDA的约2-12倍。 这些更高的水平是通过逐渐增加每日剂量来实现的，以响应患者的耐受性，直到看到有益的结果。 总镁摄入量每天分几次，并用大量的水分。

    Sponge-derived terpenoids and methods of use
    2.
    发明授权
    Sponge-derived terpenoids and methods of use 有权
    海绵衍生的萜类化合物和使用方法

    公开(公告)号：US06750247B2

    公开(公告)日：2004-06-15

    申请号：US10159772

    申请日：2002-05-31

    申请人： Phillip Crews ,  Jennifer Carroll ,  Theodore Holman ,  Guy Miller ,  Steve Bobzin ,  Lesley Brown

    发明人： Phillip Crews ,  Jennifer Carroll ,  Theodore Holman ,  Guy Miller ,  Steve Bobzin ,  Lesley Brown

    IPC分类号： A61K3119

    CPC分类号： A61K31/355 ,  A61K31/192 ,  A61K31/255 ,  A61K31/335 ,  A61K31/34 ,  A61K31/35 ,  A61K31/353 ,  A61K31/365

    摘要： Compounds that are effective lipoxygenase inhibitors, and methods and pharmaceutical compositions for inhibiting lipoxygenases and for treatment of lipoxygenase-mediated conditions in humans and other subjects. The compounds, methods and pharmaceutical compositions utilize subersic terpenoids, jaspic terpenoids, igernellic terpenoids, hippospongic terpenoids, halicondric terpenoids, dictyodendric terpenoids, and/or heteronemic terpenoids, and synthetic derivatives or analogs thereof. Exemplary compounds include (−)-subersic acid, (+)-subersin, jaspaquinol, (−)-jaspic acid, igernellin, halisufate 7, and hipposulfate C and D, and derivatives thereof.

    摘要翻译： 作为有效的脂氧合酶抑制剂的化合物，以及用于抑制脂氧合酶和用于治疗人和其他受试者中脂氧合酶介导的病症的方法和药物组合物。 化合物，方法和药物组合物利用萜类化合物，ic萜类化合物，igernellic萜类化合物，髋关节萜类化合物，卤代萜类化合物，二萜类萜类化合物和/或异源萜类化合物，及其合成衍生物或类似物。 示例性化合物包括（ - ） - subersic acid，（+） - subersin，jaspaquinol，（ - ） - jaspic acid，igernellin，halisufate 7和河pos啶C和D及其衍生物。

    Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and cosmetics
    7.
    发明授权
    Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and cosmetics 失效
    6-叔丁基-1,1-二甲基茚满的4-位不饱和衍生物及其在人兽药和化妆品中的应用

    公开(公告)号：US06534545B1

    公开(公告)日：2003-03-18

    申请号：US09579441

    申请日：2000-05-26

    申请人： Angel De Lera ,  Beatriz Dominguez

    发明人： Angel De Lera ,  Beatriz Dominguez

    IPC分类号： A61K3119

    CPC分类号： C07D333/38 ,  A61K8/31 ,  A61K8/362 ,  A61K8/37 ,  A61K8/4926 ,  A61K8/4973 ,  A61K8/4986 ,  A61Q7/00 ,  A61Q19/00 ,  A61Q19/004 ,  C07C57/50 ,  C07C63/66 ,  C07C69/618 ,  C07C69/76 ,  Y10S977/801 ,  Y10S977/905 ,  Y10S977/906 ,  Y10S977/915

    摘要： 6-tert-Butyl-1,1-dimethylindane derivatives which are unsaturated in the 4-position of formula: X represents: (i) either a radical of formula: (a)  and Y represents a radical of formula: (b) (ii) or a radical of formula: (c)  and Y represents either a radical of formula (b) or a radical of formula: Z being —O—, —S— or R1 represents —CH3, —(CH2)p—OR4, —(CH2)p—COR5 or —S(O)t—R6, p being 0, 1, 2 or 3, t being 0, 1 or 2, R2 represents H or lower alkyl, R3 represents H, lower alkyl or —COR7, R4 represents H, lower alkyl, —COR7, aryl, aralkyl, mono- or polyhydroxyalkyl, or a polyether radical, R5 represents H, lower alkyl, —OR8 or —N(r′)(r″), R6 represents H or lower alkyl, R7 represents lower alkyl, R8 represents H, alkyl, alkenyl, alkynyl, aryl, aralkyl, mono- or polyhydroxyalkyl, a sugar residue or an amino acid residue, r′ and r″ represent H, lower alkyl, —COR7, aryl, a sugar residue or an amino acid residue or r′ and r″ form a heterocycle, and the salts of the compounds of formula (I). Use in the topical and systemic treatment of dermatological conditions, as well as in cosmetics.

    摘要翻译： 式中X表示不饱和的6-叔丁基-1,1-二甲基茚满衍生物：（i）式（a）的基团和Y表示式（b）的基团（ ii）或式（c）的基团，Y表示式（b）的基团或式Z的基团是-O - ， - S-或R 1表示-CH 3， - （CH 2）p -OR 4， - （CH 2）p-COR 5或-S（O）t -R 6，p为0,1,2或3，t为0,1或2，R 2表示H或低级烷基，R 3表示H，低级烷基或 - COR7，R4代表H，低级烷基，-COR7，芳基，芳烷基，单或多羟基烷基或聚醚基，R5代表H，低级烷基，-OR8或-N（r'）（r“），R6代表 H或低级烷基，R 7表示低级烷基，R 8表示H，烷基，烯基，炔基，芳基，芳烷基，单或多羟基烷基，糖残基或氨基酸残基，r'和r“表示H，低级烷基， -COR 7，芳基，糖残基或氨基酸残基或r'和r“形成杂环，和式（I）化合物的盐。使用 皮肤病学的局部和全身治疗，以及化妆品。

    Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
    8.
    发明授权
    Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders 失效
    糖皮质激素和甲状腺激素受体配体用于治疗代谢紊乱

    公开(公告)号：US06492424B1

    公开(公告)日：2002-12-10

    申请号：US09744865

    申请日：2001-04-09

    申请人： Theresa Apelqvist ,  Patrick Goede ,  Erik Holmgren

    发明人： Theresa Apelqvist ,  Patrick Goede ,  Erik Holmgren

    IPC分类号： A61K3119

    CPC分类号： C07D295/192 ,  C07C59/68 ,  C07C59/90 ,  C07C65/40 ,  C07C69/736 ,  C07C69/92 ,  C07C217/90 ,  C07C233/56 ,  C07C235/34

    摘要： Novel glucocorticoid and thyroid receptor ligands as provided which have the general formula (I): in which R1 is an aliphatic hydrocarbon, an aromatic hydrocarbon, carboxylic acid or ester thereof, alkenyl carboxylic acid or ester thereof, hydroxy, halogen, or cyano, or a pharmaceutically acceptable salt thereof. R2 and R3 are the same or different, and are hydrogen, halogen, alkyl of 1 to 4 carbons, or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen. X is carbonyl or methylene. R4 is an aliphatic, aromatic or heteroaromatic. Y is hydroxyl, methoxy, amino, or alkyl amino. n is an integer from 0 to 4. A method for treating diseases associated with metabolism dysfunction or which are dependent on the expression of a glucocorticoid or thyroid receptor gene such as diabetes, hypercholesterolemia, or obesity using these compounds is also disclosed.

    摘要翻译： 提供具有通式（I）的新型糖皮质激素和甲状腺受体配体：其中R 1是脂族烃，芳族烃，羧酸或其酯，链烯基羧酸或其酯，羟基，卤素或氰基，或 其药学上可接受的盐。 R2和R3相同或不同，为氢，卤素，1至4个碳的烷基或3至5个碳的环烷基，R2和R3中的至少一个不是氢。 X是羰基或亚甲基。 R 4是脂族，芳族或杂芳族。 Y是羟基，甲氧基，氨基或烷基氨基。 n是0至4的整数。还公开了用于治疗与代谢功能障碍相关的疾病或依赖于使用这些化合物的糖皮质激素或甲状腺受体基因如糖尿病，高胆固醇血症或肥胖症的表达的方法。